Sort by
Search results
FVII Inhibitor Plasma (3) strong (51-200 BU/ml), frozen
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.
FXI Inhibitor Plasma (2) Moderate (11-50 BU/ml), frozen
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.
FX Inhibitor Plasma (2) Moderate (11-50 BU/ml), frozen
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.
FVIII Inhibitor Plasma (2) Moderate (11-50 BU/ml), frozen
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.
FVII Inhibitor Plasma (2) Moderate (11-50 BU/ml), frozen
Can be used as a substitute for plasmas from patients that have developed neutralizing antibodies to coagulation factors. For research use only.
HEMOCLOT Quanti. V-L
Quantitative measurement of Factor V Leiden, resistant to the action of activated protein C (APC resistance), for diagnosing patients carrying the R506Q FV mutation (Factor V Leiden), or any FV mutant resistant to APC.
Epinephrine
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g., myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.
Arachidonic Acid
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g., myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.
ADP Assay for Platelet Aggregation
Investigation of congenital (e.g. Glanzmann’s thrombasthenia, Bernard-Soulier, gray platelet syndrome) or acquired thrombopathy (e.g., myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma, hepatic or renal failure). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDs and GPIIb/IIIa inhibitors.
BIOPHEN Abnormal Control Plasma
Quality control plasma for the corresponding clotting or chromogenic assay.